<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445327</url>
  </required_header>
  <id_info>
    <org_study_id>070111</org_study_id>
    <secondary_id>07-C-0111</secondary_id>
    <nct_id>NCT01445327</nct_id>
    <nct_alias>NCT00452946</nct_alias>
  </id_info>
  <brief_title>Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers</brief_title>
  <official_title>A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Gastrointestinal cancers are among the most commonly diagnosed cancers in the United&#xD;
           States.&#xD;
&#xD;
        -  There are currently no tests to predict how patients with gastrointestinal cancers will&#xD;
           respond to radiation therapy or which patients may develop side effects from treatment.&#xD;
&#xD;
        -  Studies on tumor cells in the stool, urine, or blood from patients may provide valuable&#xD;
           information that can be used to develop tests to determine which patients may need more&#xD;
           or less aggressive therapy.&#xD;
&#xD;
        -  Studies of other substances in the stool, urine, or blood from patients may provide&#xD;
           valuable information that can be used to develop tests to determine which patients are&#xD;
           likely to develop side effects from radiation treatments.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To collect blood, urine and stool specimens from patients with gastrointestinal cancers&#xD;
           who will undergo radiation therapy.&#xD;
&#xD;
        -  To study hormone and protein changes in these blood, urine and stool specimens before,&#xD;
           during and after radiation treatment in order to develop a way to predict how&#xD;
           gastrointestinal cancers will respond to radiation therapy and if patients with these&#xD;
           cancers will develop side effects from radiation treatment.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      -Patients 18 years of age and older with cancer of the gastrointestinal tract (esophagus,&#xD;
      stomach, pancreas, rectum) who plan to receive radiotherapy to the site of the cancer on an&#xD;
      NCI protocol&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants undergo the following procedures:&#xD;
&#xD;
        -  Tumor biopsy: Before any treatment or at the time of surgery if it is the first&#xD;
           treatment&#xD;
&#xD;
        -  Urine collection: Before, during, and after treatment and at follow-up visits.&#xD;
&#xD;
        -  Stool collection: Before, during, and after treatment and at follow-up visits.&#xD;
&#xD;
        -  Blood collection: Before, during, and after treatment and at follow-up visits.&#xD;
&#xD;
        -  Intestinal permeability assessment: Before any treatment, before radiation (if radiation&#xD;
           is not the first treatment), 1 month after radiation is completed, and 3 months after&#xD;
           radiation is completed. This test determines how the patient s intestines are working to&#xD;
           absorb sugar and may provide information about side effects from radiation treatments.&#xD;
           Patients fast after midnight, then drink a small glass of sugars, and then do a 6-hour&#xD;
           urine collection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Gastrointestinal (GI) carcinomas represent one of the most commonly diagnosed&#xD;
           malignancies in the United States.&#xD;
&#xD;
        -  A sensitive and specific marker of tumor persistence or recurrence would permit a more&#xD;
           accurate determination of the appropriateness of adjuvant therapy in patients with no&#xD;
           clinical evidence of disease following curative resection and allow the diagnosis of&#xD;
           recurrences at earlier stages that may be amenable to curative salvage therapies.&#xD;
&#xD;
        -  A biomarker detectable shortly after treatment or in the early stages of chronic&#xD;
           radiation toxicity may allow the identification of patients at risk and early&#xD;
           intervention.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Our primary objective is to determine if patient specific tumor markers in stool, urine,&#xD;
           or serum can be reliably detected prior to treatment and followed after treatment to&#xD;
           monitor the extent of residual disease.&#xD;
&#xD;
        -  A second objective is to evaluate the predictive value of potential markers of chronic&#xD;
           gastrointestinal injury after radiotherapy.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Age greater than or equal to 18 years&#xD;
&#xD;
        -  Histologically confirmed carcinoma of the gastrointestinal tract (esophagus, stomach,&#xD;
           pancreas, rectum)&#xD;
&#xD;
        -  Planned to receive radiotherapy to the site of the gastrointestinal malignancy on an NCI&#xD;
           protocol&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This protocol provides a means of acquiring tissue, serum, urine, and stool samples from&#xD;
           patients who will receive radiation therapy as part of their treatment for&#xD;
           gastrointestinal malignancies.&#xD;
&#xD;
        -  Patients treated with radiation therapy on NCI treatment protocols will be asked to&#xD;
           provide samples prior to any local or systemic therapy as well as before, during and&#xD;
           after their radiation treatment.&#xD;
&#xD;
        -  These samples will be tested for the presence of tumor specific DNA mutations and&#xD;
           aberrant methylation patterns determined to be present in each patient s tumor by&#xD;
           screening of initial biopsy or surgical material.&#xD;
&#xD;
        -  Tumor markers specific to each patient, such as tumor specific DNA mutations or aberrant&#xD;
           DNA methylation, may provide an individualized method to evaluate disease status and&#xD;
           determine prognosis after therapy. Additionally, a number of stool and serum markers&#xD;
           will be explored as early indicators of acute and eventual chronic gastrointestinal&#xD;
           injury in patients receiving radiotherapy to the abdomen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 20, 2007</start_date>
  <completion_date>January 20, 2015</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">9</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Stomach Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Histologically confirmed carcinoma of the gastrointestinal tract (esophagus, stomach,&#xD;
             pancreas, bile duct, rectum).&#xD;
&#xD;
          -  Treatment plan includes radiotherapy to the site of the gastrointestinal malignancy on&#xD;
             an NCI protocol.&#xD;
&#xD;
          -  Paraffin embedded tumor tissue from biopsy or surgery adequate in amount to perform&#xD;
             PCR and methylation specific PCR or willingness to undergo rebiopsy.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Inability to provide informed consent.&#xD;
&#xD;
          -  Patients who have a history of prior therapeutic radiation.&#xD;
&#xD;
          -  Patients with evidence of distant metastases on initial staging evaluation.&#xD;
&#xD;
          -  Patients with other cancers excluding non-melanomatous skin cancers or carcinoma in&#xD;
             situ.&#xD;
&#xD;
          -  History of inflammatory bowel disease.&#xD;
&#xD;
          -  History of collagen vascular disease or disease of altered collagen metabolism (end&#xD;
             stage renal disease or hepatic fibrosis due to chronic hepatitis).&#xD;
&#xD;
          -  History of hypersensitivity to radiation or a history of a disease which results in&#xD;
             mucosal or other hypersensitivity to radiation (Ataxia-Telengiectasia, Bloom s&#xD;
             Syndrome, Human Immunodeficiency Virus, Fanconi anemia, nevoid basal cell carcinoma&#xD;
             syndrome, Li-Fraumeni syndrome, and Nijmegen breakage syndrome).&#xD;
&#xD;
          -  Inability to return for follow-up visits.&#xD;
&#xD;
          -  Patients who have previously received or are currently receiving MDX-101 (ipilimumab).&#xD;
&#xD;
          -  Diagnosis of HIV, Hepatits B, or Hepatits C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah E Citrin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30.</citation>
    <PMID>16514137</PMID>
  </reference>
  <reference>
    <citation>Seamonds B, Yang N, Anderson K, Whitaker B, Shaw LM, Bollinger JR. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology. 1986 Dec;28(6):472-9.</citation>
    <PMID>2431533</PMID>
  </reference>
  <reference>
    <citation>Guillet J, Role C, Duc AT, Fran√ßois H. Prostate-specific antigen (PSA) in the management of 500 prostatic patients. Am J Clin Oncol. 1988;11 Suppl 2:S61-2.</citation>
    <PMID>2468274</PMID>
  </reference>
  <verification_date>January 20, 2015</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood</keyword>
  <keyword>Urine</keyword>
  <keyword>Stool</keyword>
  <keyword>Tumor Marker</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Stomach</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 4, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

